8-K: Accuray Reports 19% Order Growth, Reaffirms Fiscal Year 2024 Guidance

Accuray Incorporated announced a 19% year-over-year increase in gross orders and reaffirmed its fiscal year 2024 financial guidance.

Summary

• Accuray reported a 19% year-over-year increase in gross orders for the second quarter of fiscal year 2024, reaching $93.9 million.
• The company's service revenue expanded by 8% year-over-year in the second quarter.
• Net revenue for the quarter was $107.2 million, a 7% decrease compared to the same period last year, or an 8% decrease on a constant currency basis.
• The book-to-bill ratio was 1.8 for the second quarter, up from 1.2 in the prior year.
• Accuray's GAAP net loss for the quarter was $9.6 million, compared to a $1.9 million loss in the same period last year.
• Adjusted EBITDA for the quarter was $2.0 million, down from $8.5 million in the prior year.
• For the first six months of fiscal year 2024, net revenue was $211.1 million, flat compared to the same period last year, or a 1% decrease on a constant currency basis.
• The company's GAAP net loss for the first six months was $12.6 million, compared to a $7.3 million loss in the prior year.
• Adjusted EBITDA for the first six months was $8.5 million, down from $10.4 million in the prior year.
• Accuray reaffirmed its fiscal year 2024 revenue guidance of $460 million to $470 million and adjusted EBITDA guidance of $27 million to $30 million.
• The company expects third quarter revenue to be between $112 million and $118 million with adjusted EBITDA between $6 million and $9 million.

Sentiment

Score: 5

Explanation: The document presents mixed results. While order growth is strong and the company is reaffirming guidance, the decrease in revenue and profitability raises concerns. The sentiment is neutral to slightly negative due to the financial losses and reduced profitability.

Positives

• Accuray saw a significant increase in gross orders, indicating strong demand for its products.
• The company's service revenue is growing, contributing to a more stable revenue stream.
• The book-to-bill ratio is healthy, suggesting future revenue growth.
• The Tomo C product launch in China is proving successful, driving significant order growth.
• The EIMEA region is performing well, with strong order and revenue growth.
• The company is expanding its installed base, which should lead to further service revenue growth.
• Regulatory approvals, such as the Shonin approval for VitalHold in Japan, are opening new market opportunities.
• Accuray is maintaining its full year guidance.

Negatives

• Net revenue decreased by 7% year-over-year in the second quarter, or 8% on a constant currency basis.
• GAAP net loss increased significantly in both the second quarter and the first six months of fiscal year 2024 compared to the prior year.
• Adjusted EBITDA decreased in both the second quarter and the first six months of fiscal year 2024 compared to the prior year.
• Product revenue decreased by 19% year-over-year in the second quarter.
• The order backlog is approximately 4% lower than at the end of the prior fiscal year second quarter.
• Cash, cash equivalents, and short-term restricted cash decreased by $16.7 million from June 30, 2023.

Risks

• The company faces risks related to the global macroeconomic environment, including inflation and potential recession.
• Disruptions to the supply chain, including increased logistics costs, could impact the company's operations.
• The company's ability to achieve widespread market acceptance of its products is crucial for future growth.
• Delays in regulatory approvals or the development of new offerings could negatively impact the company.
• The company's ability to meet the covenants under its credit facilities is a potential risk.
• The company's ability to convert backlog to revenue is important for financial performance.

Future Outlook

Accuray reaffirmed its fiscal year 2024 revenue guidance of $460 million to $470 million and adjusted EBITDA guidance of $27 million to $30 million. The company expects third quarter revenue to be between $112 million and $118 million with adjusted EBITDA between $6 million and $9 million.

Management Comments

• Suzanne Winter, Chief Executive Officer, stated that she is pleased with the Q2 performance, which reflects sequential growth in orders, revenue, and the installed base.
• She also noted that customer adoption of the Tomo C product in China has been excellent.
• She mentioned that interest in VitalHold on the Radixact System and preference for the CyberKnife S7 System remains strong.

Industry Context

Accuray's results reflect the ongoing demand for radiation therapy solutions in the oncology market. The company's focus on innovation, such as the Tomo C and VitalHold, aligns with industry trends towards more advanced and personalized treatment options. The growth in China and EIMEA regions highlights the importance of international markets for medical device companies.

Comparison to Industry Standards

• Accuray's 19% order growth in Q2 is a positive sign, but the 7% revenue decrease indicates potential challenges in converting orders to revenue, which is a common issue in the medical device industry.
• Competitors like Varian Medical Systems (now part of Siemens Healthineers) and Elekta also operate in the radiation therapy space, and their performance in similar periods would be a good benchmark. Varian, for example, has a large installed base and a strong service revenue stream.
• The book-to-bill ratio of 1.8 is a positive indicator for future revenue, but it needs to be sustained. Companies like Elekta also focus on maintaining a healthy book-to-bill ratio to ensure future growth.
• Accuray's adjusted EBITDA margin is lower than some of its larger competitors, indicating a need for improved operational efficiency and cost management. Varian and Elekta typically have higher EBITDA margins due to their scale and established market presence.
• The success of the Tomo C launch in China is a positive development, as the Chinese market is a key growth area for medical device companies. Other companies are also focusing on expanding their presence in China.
• The VitalHold approval in Japan is a significant milestone, as Japan is a major market for medical technology. Other companies are also seeking regulatory approvals for their products in Japan.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and decreased profitability.
• Employees may be affected by the company's cost-saving initiatives, including workforce reductions.
• Customers may benefit from the company's new product innovations and expanded access to radiotherapy.
• Suppliers may be impacted by the company's supply chain challenges.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• Accuray will host a conference call to discuss the results.
• The company will continue to execute on its three-year growth plan.
• Accuray will focus on advancing patient care through innovation and expanding access to radiotherapy.
• The company will work to improve overall profitability and working capital.

Key Dates

Keywords

Accuray, Radiation Therapy, Oncology, CyberKnife, Radixact, Tomo C, VitalHold, Orders, Revenue, EBITDA, Book-to-bill, China, Healthcare, Medical Devices